Moderna’s new bivalent booster shows superior antibody response against Omicron
June 9, 2022
Moderna’s bivalent booster shows positive results. Superior antibody response to Omicron reported.
Where: Cambridge, MA
The Facts
Moderna has announced that its new bivalent Covid-19 vaccine booster has shown a “superior antibody response” against the Omicron variant one month after administration, compared to the original mRNA vaccine.
The updated bivalent booster contains Moderna’s original Spikevax vaccine and a vaccine candidate targeting the Omicron variant of COVID-19.
The Omicron-containing bivalent booster, aka mRNA-1273.214, demonstrated an eightfold increase in neutralizing antibody levels in clinical trial participants.
Compared to Moderna’s Spikevax booster, 50 micrograms of the updated booster also yielded increased antibody levels against other variants of concern, including Alpha, Beta, Gamma, and Delta COVID-19 variants.
Moderna CEO Stéphane Bancel noted that mRNA-1273.214 was their “lead candidate for a Fall 2022 booster.”
Primary Sources
Direct, authoritative source material on this story.
Reference Articles
Articles Citable has ingested related to this story.
Reference Articles
Articles Citable has ingested related to this story.
Media Coverage
Why did we include this story
Most covered story by the media today
of articles referenced this story
Coverage by Media Outlet
Media outlets covering this story along with their positive or negative sentiment toward this story.
